Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Arlene Morris | F | 72 | 6 years | |
Angela Sheen | M | - | 4 years | |
Tomas Kiselak | M | 38 | 4 years | |
Peter Harwin | M | 38 | 4 years | |
Vahe Bedian | M | - | 4 years | |
Paul Rothman | M | 66 |
The Johns Hopkins University
| 12 years |
Bahija Jallal | M | 62 |
The Johns Hopkins University
| 10 years |
Edward G. Amoroso | M | - |
The Johns Hopkins University
| 8 years |
Ming Zhao Xing | M | 62 |
The Johns Hopkins University
| 13 years |
Essra Ridha | M | 41 | 3 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Jonathan Violin | M | 49 | 3 years | |
Sami Alom | M | 44 |
The Johns Hopkins University
| 13 years |
Lee Rauch | F | - | 1 years | |
William Marshall | M | 60 | 3 years | |
Adam Levy | M | 46 | 3 years | |
Bruce Booth | M | 49 | 12 years | |
Christopher Bowden | M | 63 | 3 years | |
Shreya Singh | F | - |
The Johns Hopkins University
| 5 years |
Lara Meisner | F | 52 | 3 years | |
Ari Charles Abramson | M | - |
The Johns Hopkins University
| 2 years |
Sam Yilmaz | M | - |
The Johns Hopkins University
| 7 years |
Charles D. Miller | M | 96 |
The Johns Hopkins University
| - |
Greco Song | M | - |
The Johns Hopkins University
| 5 years |
Sean P. McWilliams | M | - |
The Johns Hopkins University
| 9 years |
Saliq Jamil Khan | M | - |
The Johns Hopkins University
| 3 years |
Gabriel Denis | M | - |
The Johns Hopkins University
| 4 years |
Patrik Johansson | M | - |
The Johns Hopkins University
| 4 years |
Erik von Heijne | M | 34 |
The Johns Hopkins University
| 5 years |
Michael Strine | M | - |
The Johns Hopkins University
| - |
Jordan Pryor | M | - |
The Johns Hopkins University
| 5 years |
James Gettinger | M | - |
The Johns Hopkins University
| 4 years |
Thomas Hughes | M | 64 | 3 years | |
Kevin Koch | M | 63 | 3 years | |
Nikhil Panu | M | - |
The Johns Hopkins University
| 4 years |
Janielle Newland | F | - | 2 years | |
Arman Koul | M | - |
The Johns Hopkins University
| 4 years |
David Glass | M | - |
The Johns Hopkins University
| 5 years |
Marc Blaustein | M | 61 |
Akashi Therapeutics Inc
Akashi Therapeutics Inc Pharmaceuticals: MajorHealth Technology Akashi Therapeutics Inc is a clinical stage biopharmaceutical company based in Cambridge, MA with subsidiaries in the United States. The private company has been granted orphan designation for DMD in both the US and Europe. The American company's mission is to develop treatments for Duchenne muscular dystrophy and other rare pediatric diseases. Akashi is developing a cocktail of medications with the goal of transforming Duchenne from a 100% fatal, aggressive muscle-wasting disease to a chronic, manageable condition. The application of HT-100 to DMD and other fibrotic diseases is based on pioneering work by Dr. Mark Pines at the Volcani Institute. Dosing and new patient enrollment in the phase 1b/2a clinical program have been suspended. The company was founded by leading patient organizations and biotechnology industry veterans and is managed by a seasoned team of drug development experts. The company was founded by Marc B. Blaustein, Thomas C. Wicka. | 6 years |
Dennis Deng | M | - |
The Johns Hopkins University
| 5 years |
Nathan Chen | M | - |
The Johns Hopkins University
| 1 years |
Sarah Wolfe | F | - |
The Johns Hopkins University
| 2 years |
Natasha Ahmed | F | - |
The Johns Hopkins University
| 2 years |
Megan Sparks | F | - |
The Johns Hopkins University
| 3 years |
Dan Teran | M | - |
The Johns Hopkins University
| 3 years |
Alex Harding | M | - |
The Johns Hopkins University
| 6 years |
Siwei Bian | F | - |
The Johns Hopkins University
| 4 years |
Anand Patel | M | - |
The Johns Hopkins University
| 2 years |
Vincent Lin | M | - |
The Johns Hopkins University
| 4 years |
AJ Hellow | M | - |
The Johns Hopkins University
| 4 years |
Maggie Dorn | F | - |
The Johns Hopkins University
| 3 years |
Stephanie Dontas | F | - |
The Johns Hopkins University
| 4 years |
Kate Kelberg | F | - |
The Johns Hopkins University
| 4 years |
Michael Eberle | M | - |
The Johns Hopkins University
| 4 years |
Zachary Brit Yerushalmi | M | 35 |
The Johns Hopkins University
| 4 years |
Mihir Mehta | M | - |
The Johns Hopkins University
| 4 years |
Tim Shieh | M | - |
The Johns Hopkins University
| 4 years |
Suraj Shah | M | - |
The Johns Hopkins University
| 4 years |
Suborna Panja | M | - |
The Johns Hopkins University
| 4 years |
David S. Kaminsky | M | - |
The Johns Hopkins University
| 4 years |
Vishnu Joshi | M | - |
The Johns Hopkins University
| 3 years |
Diana Stern | F | - |
The Johns Hopkins University
| 4 years |
Michael C. Chang | M | - |
The Johns Hopkins University
| 4 years |
Andrea Vandersall | F | - |
The Johns Hopkins University
| 4 years |
Mark Schoenberg | M | 66 |
The Johns Hopkins University
| 9 years |
Neil M. Bouhan | M | - |
The Johns Hopkins University
| 2 years |
Nathan Horst | M | - |
The Johns Hopkins University
| 2 years |
Ivan Szpakowski | M | - |
The Johns Hopkins University
| 1 years |
Christine Peacock | F | - |
The Johns Hopkins University
| 2 years |
Lucy Webster | F | - |
The Johns Hopkins University
| 1 years |
Lynn Johnson Langer | M | - |
The Johns Hopkins University
| 14 years |
Kevin M. Moore | M | 61 |
The Johns Hopkins University
| 4 years |
Grant J. Silow | M | - |
The Johns Hopkins University
| 4 years |
Kat Cooley | F | - |
The Johns Hopkins University
| 2 years |
Jeffrey Covell | M | - |
The Johns Hopkins University
| 3 years |
Eric G. Lee | M | - |
The Johns Hopkins University
| 2 years |
Eugene Williams | M | 64 |
Akashi Therapeutics Inc
Akashi Therapeutics Inc Pharmaceuticals: MajorHealth Technology Akashi Therapeutics Inc is a clinical stage biopharmaceutical company based in Cambridge, MA with subsidiaries in the United States. The private company has been granted orphan designation for DMD in both the US and Europe. The American company's mission is to develop treatments for Duchenne muscular dystrophy and other rare pediatric diseases. Akashi is developing a cocktail of medications with the goal of transforming Duchenne from a 100% fatal, aggressive muscle-wasting disease to a chronic, manageable condition. The application of HT-100 to DMD and other fibrotic diseases is based on pioneering work by Dr. Mark Pines at the Volcani Institute. Dosing and new patient enrollment in the phase 1b/2a clinical program have been suspended. The company was founded by leading patient organizations and biotechnology industry veterans and is managed by a seasoned team of drug development experts. The company was founded by Marc B. Blaustein, Thomas C. Wicka. | 4 years |
Junaid Husain | M | - |
The Johns Hopkins University
| - |
Al Berkeley | M | 80 |
The Johns Hopkins University
| 12 years |
William Polk Carey | M | 93 |
The Johns Hopkins University
| - |
Nick A. Williams | M | - |
The Johns Hopkins University
| 1 years |
Stephen Sihelnik | M | - |
The Johns Hopkins University
| 4 years |
Cecilia Furlong | F | - |
The Johns Hopkins University
| 4 years |
Doug Drummond | M | - |
The Johns Hopkins University
| 4 years |
David Gutelius | M | - |
The Johns Hopkins University
| 3 years |
Sohel Sanghani | M | - |
The Johns Hopkins University
| 4 years |
Arnav M Mitra | M | - |
The Johns Hopkins University
| 4 years |
Harrison Wang | M | - |
The Johns Hopkins University
| 4 years |
Zhi Fei Li | M | 47 |
The Johns Hopkins University
| 3 years |
John Henry Iucker | M | - |
The Johns Hopkins University
| 4 years |
Paul Grossinger | M | - |
The Johns Hopkins University
| 5 years |
Ahmad Ishaq | M | - |
The Johns Hopkins University
| 4 years |
J. Caiado de Sousa | M | - |
The Johns Hopkins University
| 4 years |
Janet U. Jones | F | - |
The Johns Hopkins University
| 4 years |
Vincent Lin | M | - |
The Johns Hopkins University
| 4 years |
Tim McCarty | M | - |
The Johns Hopkins University
| 4 years |
Matt Groves | M | - |
The Johns Hopkins University
| 4 years |
Matthew R. Johnson | M | - |
The Johns Hopkins University
| 2 years |
Jessica L. Gartner | F | - |
The Johns Hopkins University
| 1 years |
Gugan Raghuraman | M | - |
The Johns Hopkins University
| 4 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 99 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Diana M. Escolar
- Personal Network